We preliminarily speculate that ZEN may increase the susceptibility of NAFLD by activating CYP1B1-SCD1, providing a theoretical basis for ZEN's health risk assessment and prevention and treatment of NAFLD. The gene discussed is SCD; the disease is metabolic dysfunction-associated steatotic liver disease.